Amicus Therapeutics, Inc. (Nasdaq: FOLD) has expanded its biologics pipeline with a new preclinical program for cyclin-dependent kinase-like 5 (CDKL5) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE